+

WO2001028365A1 - Supplement nutritionnel - Google Patents

Supplement nutritionnel Download PDF

Info

Publication number
WO2001028365A1
WO2001028365A1 PCT/FI2000/000899 FI0000899W WO0128365A1 WO 2001028365 A1 WO2001028365 A1 WO 2001028365A1 FI 0000899 W FI0000899 W FI 0000899W WO 0128365 A1 WO0128365 A1 WO 0128365A1
Authority
WO
WIPO (PCT)
Prior art keywords
folate
composition
folic acid
matter
subject
Prior art date
Application number
PCT/FI2000/000899
Other languages
English (en)
Inventor
Jukka T. Salonen
Sari Voutilainen
Original Assignee
Oy Jurilab Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oy Jurilab Ltd. filed Critical Oy Jurilab Ltd.
Priority to JP2001530969A priority Critical patent/JP2003511097A/ja
Priority to EP00969600A priority patent/EP1221868A1/fr
Priority to AU79272/00A priority patent/AU7927200A/en
Publication of WO2001028365A1 publication Critical patent/WO2001028365A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to a novel use of folic acid or folate, or of a functionally equivalent substance having the biochemical activity of folic acid or folate, such as folinic acid, as a dietary supplement in or for fortification of compositions of matter, such as products for ingestion or dietary intake, for example food and feedstuff s.
  • the human serum paraoxonase is an antioxidative enzyme in high density lipoproteins (HDL), which eliminates lipid soluble radicals in the circulation and protects against coronary disease .
  • HDL high density lipoproteins
  • CHD coronary heart disease
  • Paraoxonase/ arylesterase has been suggested to account for an important part of the antioxidative property of HDL 5 .
  • a lowered PON activity has been reported also in patients with myocardial infarction (MI) 2"3 .
  • the present invention is based on the finding that there is a positive correlation between circulating folate or dietary folate intake and enhanced serum PON activity.
  • Enhanced serum PON activity improves the endogenous antioxidative capacity and defences of a subject, e.g. a human, thus reducing the risk e.g. for CHD, cancer, type II diabetes and cataract, and is also associated with the process of aging.
  • the invention is directed to a method for enhancing the endogenous antioxidative defences of the body by dietary folic acid or folate supplementation.
  • folate refers to the salts and esters of folic acid. Acceptable salts include i.e. the alkali metal salts, such as the sodium salt and the methylglucamine salt. Esters of folic acid can be prepared in a manner known to the person skilled in the art.
  • the object of the invention is thus a method for the manufacture of a composition of matter for dietary intake with antioxidative defences enhancing effect, according to which method, in the said composition, folic acid or folate or a functionally equivalent substance is used as the active or effective agent.
  • the object of the invention is the use of folic acid or folate or a functionally equivalent substance as a supplement or additive for the manufacture of a composition of matter for dietary intake with antioxidative defences enhancing effect.
  • the object of the invention is a method for enhancing the antioxidative defences in a subject comprising administering, e.g. orally or parenterally, to said subject, an effective amount of folic acid or folate or a functionally equivalent substance.
  • a functionally equivalent substance of folic acid or folate is intended to mean a substance that has the biochemical activity of folic acid, for example folinic acid or a salt or ester of folinic acid.
  • subject means here a mammal, such as a human, or an animal, especially livestock or farm animals.
  • the term "effective amount” means an amount of the active agent which after administration is sufficient to enhance the serum paraoxonase activity and thus the antioxidative defences in the subject.
  • folic acid and folate can be used interchangeably.
  • the composition of matter can be any dietary, typically orally administered composition, preparation or product, such as a food or feed product, food supplement, a drug preparation, or a raw material for such a product.
  • the product to be used as the composition of matter to be supplemented or fortified by adding thereto folic acid or folate or a functionally equivalent its derivative can in principle be any type of food or feed product.
  • folic acid or its derivative in any type of food or feed product, in which it can be properly included and distributed, such as processed foods, for example meat products, such as sausages, or also other ready made foods.
  • dairy products such as milk, cheese, butter and youghurt
  • other beverages such as fruit drinks and juices
  • a dietary supplement can also be in the form of tablets, capsules, lozenges, granules, syrups, solutions, suspensions for oral administration, wherein the folic acid or folate is suitably included together with a carrier or filler substance, such as lactose, silica, glucose, starch, glycerol, diluents and solvents.
  • a carrier or filler substance such as lactose, silica, glucose, starch, glycerol, diluents and solvents.
  • dosage forms may include conventional additives such as glidants, stabilizer, colouring agents, preservatives, taste improving agents as well as a matrix to slow down absorption such as methyl cellulose or microcrystalline cellulose with colloidal anhydrous silica.
  • the amount of folic acid or the functionally equivalent substance to be included in a composition of matter for dietary intake can vary broadly depending on the type of product to be supplemented or fortified, as well as on its intake frequency and intake levels. Such amounts can easily be determined by the person skilled in the art, to provide for and secure a suitable daily total intake of the dietary supplement.
  • a typical amount for intake would be for example 15 to 1200 ⁇ g of folate per day for a subject of normal size, such as a human subject of appr. 80 kg, or a daily intake ranging from appr. 0.2 to 15 ⁇ g per kg body weight. This amount can be administered for example in bread, such as in 100 g of bread constituting a suitable single portion.
  • Serum PON enzyme activity was analyzed based on its capacity to hydrolyze paraoxon, and erythrocyte folate levels were measured by RIA.
  • erythrocyte folate levels were measured by RIA.
  • KIHD Kuopio Ischaemic Heart Disease Risk Factor Study
  • the unadjusted mean (95 % confidence interval (CI)) serum PON activity was 26.3 % lower (63.2, 47.5 to 79.0 nmol/mL/min) in the lowest fifth of erythrocyte folate concentration than in the highest fifth (85.7, 63.2 to 108.2 nmol/mL/min).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fodder In General (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Bakery Products And Manufacturing Methods Therefor (AREA)

Abstract

La présente invention concerne un procédé destiné à la fabrication d'une composition de matière servant comme apport alimentaire, telle qu'un aliment ou un produit alimentaire ou un supplément nutritionnel, destinée à renforcer le système de défense à effet antioxydant d'un sujet, tel qu'un être humain. Ce procédé est caractérisé par le fait qu'un acide folique, un folate, ou une substance dont la fonction est équivalente, est ajouté à la composition comme agent actif.
PCT/FI2000/000899 1999-10-18 2000-10-17 Supplement nutritionnel WO2001028365A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2001530969A JP2003511097A (ja) 1999-10-18 2000-10-17 栄養補助剤
EP00969600A EP1221868A1 (fr) 1999-10-18 2000-10-17 Supplement nutritionnel
AU79272/00A AU7927200A (en) 1999-10-18 2000-10-17 Dietary supplement

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI19992239 1999-10-18
FI992239A FI19992239A7 (fi) 1999-10-18 1999-10-18 Ravintotäydennys

Publications (1)

Publication Number Publication Date
WO2001028365A1 true WO2001028365A1 (fr) 2001-04-26

Family

ID=8555463

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FI2000/000899 WO2001028365A1 (fr) 1999-10-18 2000-10-17 Supplement nutritionnel

Country Status (5)

Country Link
EP (1) EP1221868A1 (fr)
JP (1) JP2003511097A (fr)
AU (1) AU7927200A (fr)
FI (1) FI19992239A7 (fr)
WO (1) WO2001028365A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001085178A1 (fr) * 2000-05-08 2001-11-15 N.V. Nutricia Preparation nutritionnelle comprenant du ribose et de l'acide folique, et utilisation medicale associee
WO2002074230A3 (fr) * 2001-03-20 2003-04-03 Jurilab Ltd Oy Molecule d'adn codant pour une variante de paraoxonase et utilisations correspondantes
WO2004066755A1 (fr) * 2003-01-16 2004-08-12 Esa Patentverwertungsa Gentur Sachsen-Anhalt Gmbh Procede de production de saucisses crues par un processus de maturation accelere
ES2302571A1 (es) * 2005-03-18 2008-07-16 Universidad Complutense De Madrid Procedimiento de obtencion de embutidos cocidos enriquecidos con acido folico.

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0595005A1 (fr) * 1992-09-14 1994-05-04 Vesta Medicines (Proprietary) Limited Compositions pharmaceutiques pour diminuer des taux de homocystéine contenant de la vitamine B6, de l'acide folique et de la vitamine B12
WO1997014422A1 (fr) * 1995-10-17 1997-04-24 Herbert Victor D Composition a complement vitaminique multiple
DE29808384U1 (de) * 1998-05-08 1998-08-06 Eckes-Granini GmbH & Co. KG, 55268 Nieder-Olm Getränk
US6121249A (en) * 1998-07-01 2000-09-19 Donald L. Weissman Treatment and prevention of cardiovascular diseases with help of aspirin, antioxidants, niacin, and certain B vitamins

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0595005A1 (fr) * 1992-09-14 1994-05-04 Vesta Medicines (Proprietary) Limited Compositions pharmaceutiques pour diminuer des taux de homocystéine contenant de la vitamine B6, de l'acide folique et de la vitamine B12
WO1997014422A1 (fr) * 1995-10-17 1997-04-24 Herbert Victor D Composition a complement vitaminique multiple
DE29808384U1 (de) * 1998-05-08 1998-08-06 Eckes-Granini GmbH & Co. KG, 55268 Nieder-Olm Getränk
US6121249A (en) * 1998-07-01 2000-09-19 Donald L. Weissman Treatment and prevention of cardiovascular diseases with help of aspirin, antioxidants, niacin, and certain B vitamins

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE CAPLUS [online] HSU YU-CHIN ET AL.: "Effects of marginal folate deficiency on folate status, antioxidant capacity and lipid peroxidation in F344 rat livers", XP002954907, accession no. STN International Database accession no. 2000:89946 *
DATABASE CAPLUS [online] PFOHL MARTIN ET AL.: "Paraoxonase 192 Gln/Arg gene polymorphism, coronary artery disease and myocardial infarction in type 2 diabetes", XP002954908, accession no. STN International Database accession no. 1999:158555 *
DIABETES, vol. 48, no. 3, 1999, pages 623 - 627 *
ZHONGHUA MINGUO YINGYANG XUEHUI ZAZHI, vol. 24, no. 3, 1999, pages 228 - 240 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001085178A1 (fr) * 2000-05-08 2001-11-15 N.V. Nutricia Preparation nutritionnelle comprenant du ribose et de l'acide folique, et utilisation medicale associee
US6420342B1 (en) 2000-05-08 2002-07-16 N.V. Nutricia Nutritional preparation comprising ribose and medical use thereof
US6548483B2 (en) 2000-05-08 2003-04-15 N.V. Nutricia Nutritional preparation comprising ribose and medical use thereof
WO2002074230A3 (fr) * 2001-03-20 2003-04-03 Jurilab Ltd Oy Molecule d'adn codant pour une variante de paraoxonase et utilisations correspondantes
US6740746B2 (en) 2001-03-20 2004-05-25 Oy Jurilab Ltd. DNA molecule encoding a variant paraoxonase and uses thereof
US7211387B2 (en) 2001-03-20 2007-05-01 Oy Jurilab Ltd. DNA molecule encoding a variant paraoxonase and uses thereof
WO2004066755A1 (fr) * 2003-01-16 2004-08-12 Esa Patentverwertungsa Gentur Sachsen-Anhalt Gmbh Procede de production de saucisses crues par un processus de maturation accelere
US7985436B2 (en) 2003-01-16 2011-07-26 Zylum Beteiligungsgesellschaft Mbh & Co. Patente Ii Kg Method of producing raw sausage, comprising an accelerated maturing process
ES2302571A1 (es) * 2005-03-18 2008-07-16 Universidad Complutense De Madrid Procedimiento de obtencion de embutidos cocidos enriquecidos con acido folico.
ES2302571B2 (es) * 2005-03-18 2009-03-16 Universidad Complutense De Madrid Procedimiento de obtencion de embutidos cocidos enriquecidos con acido folico.

Also Published As

Publication number Publication date
JP2003511097A (ja) 2003-03-25
FI19992239A7 (fi) 2001-04-19
AU7927200A (en) 2001-04-30
EP1221868A1 (fr) 2002-07-17

Similar Documents

Publication Publication Date Title
US9872844B2 (en) Compositions and methods for the reduction or prevention of hepatic steatosis
KR101809172B1 (ko) 뮤신이 없는 배지에서 배양한 아커만시아 뮤시니필라 균주 또는 이의 배양액을 유효성분으로 함유하는 대사성 질환의 예방, 개선 또는 치료용 조성물
US11547736B2 (en) Sauvignon blanc grape seed products for nonalcoholic fatty liver disease
WO2001021208A1 (fr) Supplement nutritionnel fournissant une energie et une endurance accrues
US7968529B2 (en) Use of sphingolipids for reducing high plasma cholesterol and high triacylglycerol levels
JP2009525990A (ja) 医薬組成物
US6265391B1 (en) Method for preventing peripheral nerve damage
CN114126599A (zh) 改变衰老相关分泌表型的方法和组合物
KR20210135551A (ko) 개선된 생체이용률을 갖는 중쇄 트리글리세라이드 제제 및 이와 관련된 방법
US20220387464A1 (en) Inositol phosphate-containing composition
JP2003503038A (ja) 乳を主成分とする予防的補助食品
EP4122536A1 (fr) Promoteur de production de coenzyme q et procédé de promotion de production de coenzyme q
RU2375055C2 (ru) Применение альфа-кетоглутарата и родственных соединений для снижения липидов плазмы
JP2022169385A (ja) タモギタケ又はその処理物を有効成分として含む、脂質代謝改善剤
WO2001028365A1 (fr) Supplement nutritionnel
EP3991728A1 (fr) Agent inhibiteur de fibrose hépatique et agent activateur de cellules adipeuses brunes contenant de la taxifoline
JP5584411B2 (ja) ホモシステイン低下用組成物
JP2008156264A (ja) ルイボスティーの食後高血糖および血中尿酸低下作用
Gvozdjakova et al. Cocoa consumption and prevention of cardiometabolic diseases and other chronic diseases
US20100028457A1 (en) Agent for prevention or treatment of blood glucose level elevation
US20230040395A1 (en) Composition for suppressing obesity
EP0595006A1 (fr) Compositions pharmaceutiques et diététiques contenant de la vitamin B6, de l'acide folique et de la vitamine B12 pour le traitement des maladies métaboliques des enfants
KR101699123B1 (ko) 코르티코스테론 저하용 조성물
KR20150072675A (ko) 노인 환자의 노쇠 및 노인병 증후군 예방 및 개선용 균형 영양식 조성물 및 그의 제조방법
Ashfield-Watt et al. 9 Folate, Homocysteine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2000969600

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 530969

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 10110322

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2000969600

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000969600

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载